Kaken Pharmaceutical Co (TSE:4521) EV-to-Revenue : 0.98 (As of May. 12, 2024)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kaken Pharmaceutical Co's enterprise value is 円71,000 Mil. Kaken Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was 円72,096 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-Revenue for today is 0.98.

The historical rank and industry rank for Kaken Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

TSE:4521' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.75 Med: 1.63 Max: 4.77
Current: 0.98

During the past 13 years, the highest EV-to-Revenue of Kaken Pharmaceutical Co was 4.77. The lowest was 0.75. And the median was 1.63.

TSE:4521's EV-to-Revenue is ranked better than
80.43% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.41 vs TSE:4521: 0.98

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Kaken Pharmaceutical Co's stock price is 円3520.00. Kaken Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was 円1,915.38. Therefore, Kaken Pharmaceutical Co's PS Ratio for today is 1.84.

Kaken Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Kaken Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co EV-to-Revenue Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-Revenue

Get a 7-Day Free Trial

1.54

1.42

1.24

1.01

0.94

Kaken Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.08	0.94	0.93	0.90	0.90

Competitive Comparison of Kaken Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaken Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's EV-to-Revenue falls into.

Kaken Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Kaken Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	71000.006	/	72096
	=	0.98

Kaken Pharmaceutical Co's current Enterprise Value is 円71,000 Mil.
Kaken Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円72,096 Mil.

Kaken Pharmaceutical Co (TSE:4521) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Kaken Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	3520.00	/	1915.377
	=	1.84

Kaken Pharmaceutical Co's share price for today is 円3520.00.
Kaken Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,915.38.

Kaken Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines